The acquisition of HUB Organoids reflects the strategy of MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, to enable wider access to HUB’s technology for more effective, faster, and more ethical drug development.
“HUB’s intellectual property and service expertise around organoids further strengthens our robust portfolio in 3D cell culture and next-generation biology,” said Heather Hargett, PhD, head of Cell Biology Reagents & Tools at MilliporeSigma. “We are committed to our existing partners and look forward to enabling faster market adoption by delivering cutting-edge capabilities to advance the field of next-generation biology.”
The promise of organoids aligns with regulatory agency advocacy on the use of NAM and directly contributes to MilliporeSigma’s sustainability ambitions. The use of organoids may allow researchers to limit their reliance on animal testing by reducing stages in the R&D process—as outlined in the FDA Modernization Act 2.0/3.0 and Directive 2010/63/EU—thus positively contributing to more environmentally sustainable alternatives.
Organoids also create opportunities for genetically diverse populations to be reflected in research to allow scientists to better understand drug interactions in patient populations that can be underrepresented in clinical trials.
“As a global company with operations around the world, our top priority remains ensuring that patients, researchers, and customers worldwide continue to benefit from our innovations without disruption,” emphasized Hargett.
The post MilliporeSigma Integrates HUB appeared first on GEN - Genetic Engineering and Biotechnology News.
“HUB’s intellectual property and service expertise around organoids further strengthens our robust portfolio in 3D cell culture and next-generation biology,” said Heather Hargett, PhD, head of Cell Biology Reagents & Tools at MilliporeSigma. “We are committed to our existing partners and look forward to enabling faster market adoption by delivering cutting-edge capabilities to advance the field of next-generation biology.”
The promise of organoids aligns with regulatory agency advocacy on the use of NAM and directly contributes to MilliporeSigma’s sustainability ambitions. The use of organoids may allow researchers to limit their reliance on animal testing by reducing stages in the R&D process—as outlined in the FDA Modernization Act 2.0/3.0 and Directive 2010/63/EU—thus positively contributing to more environmentally sustainable alternatives.
Organoids also create opportunities for genetically diverse populations to be reflected in research to allow scientists to better understand drug interactions in patient populations that can be underrepresented in clinical trials.
“As a global company with operations around the world, our top priority remains ensuring that patients, researchers, and customers worldwide continue to benefit from our innovations without disruption,” emphasized Hargett.
The post MilliporeSigma Integrates HUB appeared first on GEN - Genetic Engineering and Biotechnology News.